Correction to Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial (Lancet Oncol (2018) 19 (51–64)(S1470204517309002)(10.1016/S1470-2045(17)30900-2));Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

The Lancet Oncology

Volumn 19, Issue 1, 2018, Pages 51-64

  Patel, Manish R ^a   Ellerton, John ^b   Infante, Jeffrey R ^c   Agrawal, Manish ^d   Gordon, Michael ^e   Aljumaily, Raid ^f   Britten, Carolyn D ^g   Dirix, Luc ^h   Lee, Keun Wook ⁱ   Taylor, Mathew ^j   Schöffski, Patrick ^k   Wang, Ding ^l   Ravaud, Alain ^m   Gelb, Arnold B ⁿ   Xiong, Junyuan ⁿ   Rosen, Galit ⁿ   Gulley, James L ^o   Apolo, Andrea B ^o  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Nevada Cancer Research Institute   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d Associates in Oncol and Hematology   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f University of Oklahoma Medical Center   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h SINT AUGUSTINUS HOSPITAL   (Belgium)

ⁱ Seoul National University Bundang Hospital   (South Korea)

^j OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^k UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^l HENRY FORD HOSPITAL   (United States)

^m HÔPITAL SAINT ANDRÉ   (France)

ⁿ EMD Serono Research and Development Institute Inc   (United States)

^o NATIONAL CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTINEOPLASTIC METAL COMPLEX; ASPARTATE AMINOTRANSFERASE; AVELUMAB; CISPLATIN; CREATINE KINASE; GAMMA GLUTAMYLTRANSFERASE; PROGRAMMED DEATH 1 LIGAND 1; TRIACYLGLYCEROL LIPASE; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX; PLATINUM DERIVATIVE;

ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; AGED; ARTICLE; ASTHENIA; AUTOIMMUNE HEPATITIS; BACKACHE; CANCER GROWTH; COHORT ANALYSIS; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROCOLITIS; FATIGUE; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; GUILLAIN BARRE SYNDROME; HUMAN; HYPERKALEMIA; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFUSION RELATED REACTION; LEUKOCYTOSIS; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; METASTASIS; METASTATIC UROTHELIAL CARCINOMA; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RASH; RHEUMATOID ARTHRITIS; SIDE EFFECT; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE; UVEITIS; ANTAGONISTS AND INHIBITORS; ASIA; CARCINOMA; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG EFFECT; EUROPE; IMMUNOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; SECONDARY; TIME FACTOR; TREATMENT FAILURE; UNITED STATES; URINARY TRACT TUMOR; UROTHELIUM;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ASIA; B7-H1 ANTIGEN; CARCINOMA; DISEASE-FREE SURVIVAL; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PLATINUM COMPOUNDS; TIME FACTORS; TREATMENT FAILURE; UNITED STATES; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 85037039243     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(18)30453-4     Document Type: Erratum

References (38)

1. Ferlay, J, Soerjomataram, I, Dikshit, R, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortalitiy worldwide: IARC CancerBase no. 11. 2013, International Agency for Research on Cancer, Lyon, France http://globocan.iarc.fr (accessed July 6, 2017).
2. National Cancer Institute, Surveillance, Epidemiology, End Results Program. SEER stat fact sheets: bladder cancer. https://seer.cancer.gov/statfacts/html/urinb.html, 2016 (accessed July 6, 2017).
3. Chism, DD, Apolo, AB, Milowsky, MI, Chemotherapy for metastatic bladder cancer. Xylinas, E, Shariat, SF, (eds.) Advances in bladder cancer management, 2015, Future Science Group, London, UK, 206–220.
4. Bellmunt, J, Choueiri, TK, Fougeray, R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28 (2010), 1850–1855.
5. NCCN. NCCN clinical practice guidelines in oncology (NCCN guidelines) for bladder cancer. https://www.nccn.org/professionals/physician_gls/pdf/bladder.pdf, 2017 (accessed June 6, 2017).
6. Kaufman, D, Raghavan, D, Carducci, M, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18 (2000), 1921–1927.
7. von der Maase, H, Hansen, SW, Roberts, JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 18 (2000), 3068–3077.
8. Sternberg, CN, de Mulder, PH, Schornagel, JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol 19 (2001), 2638–2646.
9. Gupta, S, Gill, D, Poole, A, Agarwal, N, Systemic immunotherapy for urothelial cancer: Current trends and future directions. Cancers, 2017 published online Jan 27. DOI:10.3390/cancers9020015.
10. Galsky, MD, Hahn, NM, Rosenberg, J, et al. Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy. J Clin Oncol 29 (2011), 2432–2438.
11. Bellmunt, J, Theodore, C, Demkov, T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 27 (2009), 4454–4461.
12. Vaughn, DJ, Broome, CM, Hussain, M, Gutheil, JC, Markowitz, AB, Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20 (2002), 937–940.
13. Galsky, MD, Mironov, S, Iasonos, A, Scattergood, J, Boyle, MG, Bajorin, DF, Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 25 (2007), 265–270.
14. McCaffrey, JA, Hilton, S, Mazumdar, M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 15 (1997), 1853–1857.
15. Buchbinder, EI, Desai, A, CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition. Am J Clin Oncol 39 (2016), 98–106.
16. Hahn, N, Powles, T, Massard, C, et al. Updated efficacy and tolerability of durvalumab in locally advanced or metastatic urothelial carcinoma (UC). Proc Am Soc Clin Oncol, 35, 2017 (abstr 4525).
17. Sharma, P, Retz, M, Siefker-Radtke, A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18 (2017), 312–322.
18. Plimack, ER, Bellmunt, J, Gupta, S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol 18 (2017), 212–220.
19. Apolo, AB, Infante, JR, Balmanoukian, A, et al. Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase 1b study. J Clin Oncol 35 (2017), 2117–2124.
20. Balar, AV, Galsky, MD, Rosenberg, JE, et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389 (2017), 67–76.
21. Bajorin, DF, de Wit, R, Vaugh, DJ, et al. Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). J Clin Oncol, 35, 2017 abstr 4501.
22. Sharma, P, Callahan, MK, Bono, P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol 17 (2016), 1590–1598.
23. Rosenberg, JE, Hoffman-Censits, J, Powles, T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (2016), 1909–1920.
24. Nakanishi, J, Wada, Y, Matsumoto, K, Azuma, M, Kikuchi, K, Ueda, S, Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 56 (2007), 1173–1182.
25. Boorjian, SA, Sheinin, Y, Crispen, PL, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14 (2008), 4800–4808.
26. Bellmunt, J, Mullane, SA, Werner, L, et al. Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. Ann Oncol 26 (2015), 812–817.
27. Scheel, AH, Dietel, M, Heukamp, LC, et al. Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas. Mod Pathol 29 (2016), 1165–1172.
28. Heery, CR, O'Sullivan-Coyne, G, Madan, RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol 18 (2017), 587–598.
29. Boyerinas, B, Jochems, C, Fantini, M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 3 (2015), 1148–1157.
30. Fujii, R, Friedman, ER, Richards, J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget 7 (2016), 33498–33511.
31. Kelly, K, Infante, JR, Taylor, MH, et al. Safety profile of avelumab in patients with advanced solid tumors: A JAVELIN pooled analysis of phase 1 and 2 data. Proc Am Soc Clin Oncol, 35, 2017 (abstr 3059).
32. Gulley, JL, Rajan, A, Spigel, DR, et al. Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial. Lancet Oncol 18 (2017), 599–610.
33. Nielsen, M, Lundegaard, C, Blicher, T, et al. NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One, 2, 2007, e796.
34. Vaughn, DJ, Srinivas, S, Stadler, WM, et al. Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma: Results of a large phase 2 study. Cancer 115 (2009), 4110–4117.
35. Novotny, JF Jr, Cogswell, J, Inzunza, H, Harbison, C, Horak, C, Averbuch, S, Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy. Ann Oncol 27 (2016), 1966–1969.
36. Feng, Z, Schlichting, M, Helwig, C, et al. Comparative study of two PD-L1 expression assays in patients with non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol, 35, 2017 (abstr e20581).
37. Sweis, RF, Galsky, MD, Emerging role of immunotherapy in urothelial carcinoma-immunobiology/biomarkers. Urol Oncol 34 (2016), 556–565.
38. Kaufman, HL, Russell, J, Hamid, O, et al. Avelumab in patients with chemotherapy-refractory metastatic merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol 17 (2016), 1374–1385.